EQS-News

INTCO Medical Reports 2025 Results with Resilient Growth, Revenue Reaches Four-Year High as Industry Rebalances 29.04.2026, 11:00 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: INTCO MEDICAL / Key word(s): Annual Results
INTCO Medical Reports 2025 Results with Resilient Growth, Revenue Reaches Four-Year High as Industry Rebalances

29.04.2026 / 11:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


ZIBO, China, April 29, 2026 /PRNewswire/ -- INTCO Medical ("INTCO" or "the Company"), a leading global manufacturer of disposable gloves, reported its 2025 annual results, with revenue reaching RMB 9.93 billion (approximately US$1.46 billion), up 4.23% year over year and marking a four-year high.

The company's annualized production capacity for disposable non-latex gloves reached 103 billion pieces, including 70 billion nitrile gloves, placing INTCO among the world's largest disposable glove manufacturers by production capacity and a top global nitrile glove manufacturer.

Intco Medical Business Segments: Medical Consumables, Rehabilitation Medical Equipment and Physical Therapy

During the reporting period, INTCO maintained stable operations amid industry rebalancing. Net profit attributable to shareholders reached RMB 1.01 billion (approximately US$148.03 million), while total assets exceeded RMB 40 billion (approximately US$5.86 billion), up 15.77% year over year. Gross margin rose 0.48 percentage points to 24.12%, and net cash flow from operating activities increased 74.69% to RMB 1.89 billion (approximately US$277.00 million), supporting the company's global expansion and long-term growth.

Scale and Manufacturing Capabilities Strengthen Core Business

Disposable gloves remained INTCO Medical's core business. As of the end of 2025, the company operated 10 R&D and manufacturing bases worldwide, with annualized capacity for disposable non-latex gloves reaching 103 billion pieces, including 70 billion nitrile gloves and 33 billion vinyl gloves.

The company continued to enhance its automated production systems, self-developed production lines and precision DCS systems to improve production efficiency, energy utilization and product quality. Its production scale remained among the industry's largest, with product yield continuing to stay above 99%.

With a global development strategy, INTCO Medical expanded overseas production capacity, including new facilities in Vietnam, strengthening supply chain resilience, supporting stable delivery and enhancing responsiveness to regional demand.

Beyond its core glove business, INTCO expanded its healthcare and personal protection portfolio, with rehabilitation medical equipment and physical therapy businesses growing and supporting a more balanced revenue mix.

Global Reach, Innovation and Digitalization Support Long-Term Growth

Investment in innovation remained a key strategic priority. In 2025, research and development spending reached RMB 404 million (approximately US$59.21 million), representing 4.07% of revenue and significantly above the industry average, reflecting the company's continued commitment to innovation.

The company continued to advance new materials, automation technologies, and product development, including the launch of innovative products such as Syntex™ Synthetic Disposable Latex Gloves and Synmax Pro Exam Gloves. Total patent holdings continued to grow, strengthening long-term competitive barriers.

INTCO continued to deepen its global market network, serving more than 15,000 customers across more than 150 countries and regions. Supported by a global marketing team of nearly 500 professionals, the company has established marketing and service centers in the U.S., Canada, Germany, Japan, Malaysia, Singapore and Hong Kong SAR, China, with plans to further expand in the Middle East, South America and Oceania to better support local customers.

INTCO is integrating digital technologies and AI across its operations, using data platforms and AI-driven tools to improve efficiency, decision-making and internal capabilities. The company continued to advance its ESG practices, including wind and solar projects that generated 12,537.23 MWh of clean energy in 2025, supporting sustainable development.

Looking ahead, INTCO will leverage its scale, technology and global network to strengthen its healthcare supply chain, improve efficiency, expand overseas capacity and accelerate product innovation.

About INTCO Medical

INTCO Medical is a leading global manufacturer of disposable gloves. As a high-tech manufacturing company, INTCO specializes in the R&D, production and marketing of medical consumables and durable medical equipment. The company's core business segments include medical consumables, rehabilitation medical equipment and physical therapy. For more information, please visit https://www.intcomedical.com/.

Photo - https://mma.prnewswire.com/media/2968835/img_v3_02115_865bd723_e54a_4c2d_8812_ea744b9462bg.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/intco-medical-reports-2025-results-with-resilient-growth-revenue-reaches-four-year-high-as-industry-rebalances-302756990.html

rt.gif?NewsItemId=EN46563&Transmission_Id=202604290456PR_NEWS_EURO_ND__EN46563&DateId=20260429


29.04.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2317826  29.04.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer